Diversify Advisory Services LLC Acquires 2,151 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Diversify Advisory Services LLC raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 42.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,227 shares of the medical equipment provider's stock after buying an additional 2,151 shares during the period. Diversify Advisory Services LLC's holdings in Intuitive Surgical were worth $3,957,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ISRG. LVW Advisors LLC grew its position in Intuitive Surgical by 1.3% during the 4th quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider's stock worth $756,000 after acquiring an additional 19 shares during the last quarter. Hazlett Burt & Watson Inc. grew its holdings in shares of Intuitive Surgical by 5.8% during the third quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock worth $177,000 after purchasing an additional 20 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. increased its stake in shares of Intuitive Surgical by 4.1% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock valued at $247,000 after buying an additional 20 shares in the last quarter. Fragasso Financial Advisors Inc raised its holdings in shares of Intuitive Surgical by 3.0% in the fourth quarter. Fragasso Financial Advisors Inc now owns 687 shares of the medical equipment provider's stock valued at $359,000 after buying an additional 20 shares during the last quarter. Finally, Ullmann Wealth Partners Group LLC lifted its position in Intuitive Surgical by 1.6% during the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock worth $653,000 after buying an additional 21 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded up $8.56 during midday trading on Monday, reaching $592.64. 2,630,118 shares of the stock were exchanged, compared to its average volume of 1,158,623. Intuitive Surgical, Inc. has a 12 month low of $362.14 and a 12 month high of $597.68. The company has a market capitalization of $211.09 billion, a price-to-earnings ratio of 95.28, a P/E/G ratio of 4.66 and a beta of 1.39. The business has a 50-day simple moving average of $540.66 and a two-hundred day simple moving average of $499.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Equities research analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, CFO Jamie Samath sold 270 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,730,093.55. This trade represents a 2.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the business's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $506.52, for a total value of $95,225.76. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,788,899.12. The trade was a 3.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,190 shares of company stock valued at $25,012,927 over the last 90 days. 0.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ISRG shares. Royal Bank of Canada raised their price objective on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an "outperform" rating in a research report on Friday, October 18th. Robert W. Baird boosted their price objective on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Evercore ISI reiterated a "cautious" rating on shares of Intuitive Surgical in a research report on Friday, October 18th. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $495.00 to $575.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Finally, Truist Financial lifted their price objective on Intuitive Surgical from $570.00 to $640.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $554.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.